Fiasp is the first and only fast-acting mealtime insulin injection that does not need a pre-meal dosing recommendation, according to the company. It is available as multiple daily injections, a continuous subcutaneous insulin infusion pump and as an intravenous infusion to be given under supervision by a healthcare professional.
Mealtime insulin dosing can be difficult because it is hard to gauge exactly how much or how quickly children will eat. Traditional rapid-acting insulins need to be administered ahead of meals, which requires guesswork to dose properly. Fiasp is designed to mitigate that problem and can be given ahead of meals or within 20 minutes of starting a meal.
Read the full news release here.
More articles on pharmacy:
Walgreens secures enterprisewide specialty accreditation
Drug price hike update: Merck, Allergen, Novartis raise prices
Regeneron restructures, cuts at least 15 jobs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.